tiprankstipranks
Trending News
More News >
InMed Pharmaceuticals (INM)
NASDAQ:INM
Advertisement

InMed Pharmaceuticals (INM) Stock Statistics & Valuation Metrics

Compare
380 Followers

Total Valuation

InMed Pharmaceuticals has a market cap or net worth of $5.01M. The enterprise value is -$3.87M.
Market Cap$5.01M
Enterprise Value-$3.87M

Share Statistics

InMed Pharmaceuticals has 2,384,186 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,384,186
Owned by Insiders16.22%
Owned by Institutions<0.01%

Financial Efficiency

InMed Pharmaceuticals’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -56.08%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-56.08%
Return on Capital Employed (ROCE)-0.56
Revenue Per Employee380.11K
Profits Per Employee-460.83K
Employee Count13
Asset Turnover0.32
Inventory Turnover3.37

Valuation Ratios

The current PE Ratio of InMed Pharmaceuticals is ―. InMed Pharmaceuticals’s PEG ratio is 0.00002.
PE Ratio
PS Ratio0.00064
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF-0.41
Price to Operating Cash Flow>-0.01
PEG Ratio0.00002

Income Statement

In the last 12 months, InMed Pharmaceuticals had revenue of 4.94M and earned -8.16M in profits. Earnings per share was -8.00.
Revenue4.94M
Gross Profit1.71M
Operating Income-7.70M
Pretax Income-8.16M
Net Income-8.16M
EBITDA-7.70M
Earnings Per Share (EPS)-8.00

Cash Flow

In the last 12 months, operating cash flow was -5.70M and capital expenditures 0.00, giving a free cash flow of -5.70M billion.
Operating Cash Flow-5.70M
Free Cash Flow-5.70M
Free Cash Flow per Share-2.39

Dividends & Yields

InMed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.76
52-Week Price Change-63.79%
50-Day Moving Average2.22
200-Day Moving Average2.80
Relative Strength Index (RSI)42.70
Average Volume (3m)113.41K

Important Dates

InMed Pharmaceuticals upcoming earnings date is Nov 13, 2025, Before Open (Confirmed).
Last Earnings DateSep 23, 2025
Next Earnings DateNov 13, 2025
Ex-Dividend Date

Financial Position

InMed Pharmaceuticals as a current ratio of 6.99, with Debt / Equity ratio of 2.28%
Current Ratio6.99
Quick Ratio6.47
Debt to Market Cap96.39
Net Debt to EBITDA1.44
Interest Coverage Ratio0.00

Taxes

In the past 12 months, InMed Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

InMed Pharmaceuticals EV to EBITDA ratio is 1.44, with an EV/FCF ratio of 1.39K.
EV to Sales-2.18
EV to EBITDA1.44
EV to Free Cash Flow1.39K
EV to Operating Cash Flow1.39K

Balance Sheet

InMed Pharmaceuticals has $11.17M in cash and marketable securities with $744.37K in debt, giving a net cash position of $10.42M billion.
Cash & Marketable Securities$11.17M
Total Debt$744.37K
Net Cash$10.42M
Net Cash Per Share$4.37
Tangible Book Value Per Share$12.10K

Margins

Gross margin is 34.53%, with operating margin of -155.89%, and net profit margin of -165.14%.
Gross Margin34.53%
Operating Margin-155.89%
Pretax Margin-165.14%
Net Profit Margin-165.14%
EBITDA Margin-151.59%
EBIT Margin0.00%

Analyst Forecast

The average price target for InMed Pharmaceuticals is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target$2.50
Price Target Upside19.05% Upside
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast7.50%
EPS Growth Forecast65.86%

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis